• RSS
    • Twitter
    • Facebook
    • Email
    • LinkedIn
    Partner Therapeutics
    • About PTx
      • Leadership
      • Compliance
      • Business Development
      • Careers
      • News
    • Medicines
    • Research
      • Our Approach
      • Sargramostim
        • Clinical Trials
        • Publications
      • Zenocutuzumab
        • About
        • Clinical Trials
        • Publications
    • Medical Info
      • Medical Inquiries
    • Contact Us
      • Contact Information
      • Lexington, MA
      • Lynnwood, WA

    Zenocutuzumab-zbco (BIZENGRI®) Shows Durable Efficacy in Patients with Treatment-Naïve NRG1+NSCLC: Updated eNRGy Trial Results Presented at IASLC-ASCO NACLC

     

    Continue Reading →
    6
    DEC
    2025
    0

    Press Release

    Search

    Archives

    • December 2025 (1)
    • October 2025 (1)
    • September 2025 (1)
    • June 2025 (1)
    • February 2025 (1)
    • January 2025 (1)
    • December 2024 (2)
    • April 2024 (2)
    • January 2024 (1)
    • December 2023 (1)
    • November 2023 (1)
    • December 2022 (1)
    • March 2022 (1)
    • February 2022 (1)
    • September 2021 (1)
    • August 2021 (1)
    • June 2021 (1)
    • May 2021 (1)
    • April 2021 (1)
    • March 2021 (2)
    • February 2021 (2)
    • September 2020 (2)
    • August 2020 (2)
    • June 2020 (1)
    • May 2020 (1)
    • March 2020 (1)
    • November 2019 (1)
    • September 2019 (1)
    • November 2018 (1)
    • June 2018 (1)
    • May 2018 (1)
    • March 2018 (1)
    • February 2018 (3)
    • January 2018 (1)
     
     

    Latest News

    •  

      Zenocutuzumab-zbco (BIZENGRI®) Shows Durable Efficacy in Patients with Treatment-Naïve NRG1+NSCLC: Updated eNRGy Trial Results Presented at IASLC-ASCO NACLC

      ...

    •  

      Zenocutuzumab-zbco Granted FDA Breakthrough Therapy Designation for NRG1+ Cholangiocarcinoma; Data Highlighting Potential of Zenocutuzumab-zbco in NRG1+ Cholangiocarcinoma to be Presented at AACR-NCI-EORTC

      ...

    •  

      Partner Therapeutics Receives EMA Approval of IMREPLYS® (sargramostim, rhu GM-CSF) to Treat Exposure to Myelosuppressive Doses of Radiation (Hematopoietic Sub-syndrome of Acute Radiation Syndrome [H-ARS])

      ...


    Join Our Team

    Partner Therapeutics (PTx) is a commercial biotech committed to improving the lives of patients with cancer and other serious diseases. We're looking for passionate professionals to join us with expertise that spans the biopharma value chain.

     

    View Current Openings
      © 2025 Partner Therapeutics, Inc. PTx-2500001
    • Home
    • News
    • Privacy Policy
    • Terms of Use

    PARTNER THERAPEUTICS and are registered trademarks of Partner Therapeutics, Inc
    BIZENGRI® is a registered trademark of Merus N.V.
    LEUKINE is a registered trademark licensed to Partner Therapeutics, Inc.